Life Sciences
More
-
SAN DIEGO-- Biopharmaceutical company Halozyme Therapeutics Inc. said Thursday that it has named David Ramsay as chief financial officer, replacing Kurt Gustafson. Gustafson had been an executive at Amgen Inc. before he joined Halozyme in 2009. Halozyme said he was leaving the company to pursue other opportunities.
-
CHICAGO, May 23- Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
-
Bristol-Myers Squibb could be a big winner with a portfolio of cancer treatments under development that use a patient's own immune system to attack the disease, according to a Citi, which raised its rating on the drugmaker.
-
*Potential sales of $35 bln a year over next 10 years- Citigroup. That bullish sales forecast by analysts at U.S. bank Citigroup highlights the growing excitement surrounding so-called immunotherapy after positive results from clinical trials conducted by companies such as Bristol-Myers Squibb and Roche Holding.
-
The number of women choosing to have preventive mastectomies has risen by almost 50 percent in recent years, and surveys show they are happy with the decision.
-
LAKE FOREST, Ill.-- Drug and medical device maker Hospira Inc. said Tuesday that Dr.
-
NEW YORK-- PDI Inc., which provides sales and marketing services to the biopharmaceutical industry, said Monday that it turned a profit in the first quarter. Net income was $2.1 million, or 14 cents per share. The company had a loss of $272,000, or 2 cents per share, a year ago.
-
NEW YORK, May 7- In a blow for Alzheimer's patients, Baxter International Inc said it will scrap late-stage trials of its antibody treatment for the disease after the drug failed to improve cognitive decline and functional ability in patients.
-
NEW YORK, May 7- In a blow for Alzheimer's patients, Baxter International Inc said it will scrap late-stage trials of its antibody treatment for the disease after the drug failed to improve cognitive decline and functional ability in patients.
-
Shares in Spanish blood plasma products maker Grifols fall 5.6 percent after news that U.S. peer Baxter's drug to moderate Alzheimer's disease has failed in a late-stage study.
-
David Blech, 57, pleaded guilty in May 2012 to securities fraud charges stemming from improper trades in biopharmaceutical companies Pluristem Therapeutics Inc and Intellect Neurosciences Inc. District Judge Colleen McMahon in Manhattan expressed anger at his repeat offense and rejected his lawyer's request for leniency.
-
**APPLE INC, $447.94, up 2 pct. William Blair& Co analyst Anil Doradla said the bond oversubscription showed investor confidence in Apple, adding that shareholders will get these benefits, and that capital allocation is driving the shares up. **AVEO PHARMACEUTICALS INC, $2.69, down 49 pct.
-
**GENERAL MOTORS CO, $31.5, up 4 pct. **VISA INC, $170.8, up 3 pct. **FACEBOOK INC, $28.17, up 3 pct.
-
U.S. stocks extended their advance on Thursday, with the Nasdaq Composite up 1 percent, led by gains in shares of Apple and Gilead Sciences. **GILEAD SCIENCES INC, $52.88, up 5 pct.
-
The FTSE Small Cap index sheds 0.1 percent in early deals, underperforming its larger peers with the FTSE 100 up 0.4 percent and the FTSE 250 rising 0.3 percent. Renold, a supplier of industrial chains and related power transmission products, falls 2.4 percent after it reports challenging conditions across all end markets in its latest trading update.
-
April 30- PDL BioPharma Inc:. *Appoints Peter Garcia as chief financial officer. *Garcia joins PDL from Biotime, Inc.
-
*Two UK studies to test gene therapy in heart failure. LONDON, April 30- British scientists are stepping up clinical tests of gene therapy in a bid to help people with advanced heart failure pump blood more efficiently.
-
Stocks fell as the broadest measure of U.S. economic growth fell short of expectations in the first quarter and Amazon.com gave a disappointing outlook. **CHEVRON CORP, $120.06, up 1.3 pct. **AMAZON.COM INC, $255.52, down 7 pct.
-
*National institute of allergy& infectious diseases will stop administering. injections in HVTN505 clinical trial of investigational HIV vaccine. *An independent data and safety monitoring board found vaccine regimen did not.
-
April 25- Theravance plans to split into two publicly traded U.S. companies, separating some of its most advanced respiratory drugs under development with GlaxoSmithKline Plc from its other biopharmaceutical operations.